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Introduction: Cardiovascular diseases (CVDs) are the leading cause of 
death in India. The CVD risk approach is a cost-effective way to identify 
those at high risk, especially in a low resource setting. As there is no 
validated prognostic model for an Indian urban population, we have 
re-calibrated the original Framingham model using data from two 
urban Indian studies. 
Methods: We have estimated three risk score equations using three 
different models. The first model was based on Framingham original 
model; the second and third are the recalibrated models using risk 
factor prevalence from CARRS (Centre for cArdiometabolic Risk 
Reduction in South-Asia) and ICMR (Indian Council of Medical 
Research) studies, and estimated survival from WHO 2012 data for 
India. We applied these three risk scores to the CARRS and ICMR 
participants and estimated the proportion of those at high-risk (>30% 
10 years CVD risk) who would be eligible to receive preventive 
treatment such as statins. 
Results: In the CARRS study, the proportion of men with 10 years CVD 
risk > 30% (and therefore eligible for statin treatment) was 13.3%, 
21%, and 13.6% using Framingham, CARRS and ICMR risk models, 
respectively. The corresponding proportions of women were 3.5%, 
16.4%, and 11.6%. In the ICMR study the corresponding proportions of 
men were 16.3%, 24.2%, and 16.5% and for women, these were 5.6%, 
20.5%, and 15.3%. 
Conclusion: Although the recalibrated model based on local 
population can improve the validity of CVD risk scores our study 
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exemplifies the variation between recalibrated models using different 
data from the same country. Considering the growing burden of 
cardiovascular diseases in India, and the impact that the risk approach 
has on influencing cardiovascular prevention treatment, such as 
statins, it is essential to develop high quality and well powered local 
cohorts (with outcome data) to develop local prognostic models.
Keywords 
CVD risk score prognostic model, the re-calibrated Framingham risk 
score
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Introduction
Currently, cardiovascular diseases (CVDs) account for two-
thirds of the total non-communicable disease (NCD) burden in 
India1. According to the 2016 Global Burden of Disease study, 
ischemic heart disease was the leading cause of the Disability-
adjusted life years (DALYs), measured to be 3062 per 100,000 
population in India2. Also, the all-age death rate increased sig-
nificantly between 1990 and 2016 for ischaemic heart disease 
(percentage change 54·5%), and CVDs are the leading cause of 
death in most parts of India2,3. Age adjusted prevalence of CVDs 
have also increased in India4,5. Indians are affected by CVDs 
at a younger age compared to their European counterparts, with 
more than 50% CVDs deaths occurring before the age of 706–8. 
The World Health Organization (WHO) had estimated that, 
due to the burden of CVDs, India had lost 237 billion dollars 
over ten years (2005–2015)9.
CVDs risk approach is a cost-effective means to identify those 
at high risk so that immediate short and long-term preventive 
steps can be followed to mitigate the risk10. Risk stratifica-
tion approach has been primarily found to be cost-effective in 
resource-poor settings11.
Although risk factor effect can be similar across populations, 
the estimated cardiovascular disease risk from risk models 
differs substantially across populations. This is mainly because 
of the different “baseline incidence of the risk model outcome” 
and prevalence of the different risk factors across populations. 
Also, a meta-analysis based on 17 population-based cohorts 
worldwide has shown that ethnicity modifies the association 
between risk factors and cardiovascular disease12. Another 
study from the United Kingdom has shown the CVD risk 
prediction model to be inaccurate in the South Asian group 
as compared to white Europeans13. Studies have also proved 
that the Framingham risk prediction model underestimates the 
CVD risk in Asian Indians and socioeconomically deprived 
individuals14,15.
The Framingham risk equation is a well-established and widely 
used method to measure cardiovascular disease (CVD) risk, 
but was developed with a white US-based population several 
decades ago and so, there is a need to re-calibrate it when 
applying it in other populations. Recalibrating a risk equation to 
a new population involves estimating the average values of the 
risk factors and the average risk of CVD. These values are used 
as the reference values in the risk model equations. To the best of 
our knowledge, only one study has recalibrated the Framingham 
risk equation in India, and this was for a rural population16. 
As there is no validated prognostic model for an Indian urban 
population, we have re-calibrated the original Framingham 
model. In this paper, we report the Framingham model rec-
alibration to an Indian urban population using data from two 
studies: CARRS (Centre for cArdiometabolic Risk Reduction in 
South-Asia), and ICMR (Indian Council of Medical Research). 
We compare the 10-year predictions of CVD fatal and non- 
fatal events produced by the original Framingham model and 
the recalibrated models and describe the potential impact of 
the recalibration on the proportion of the population eligible 
for treatment as recommended by current WHO guidelines.
Methods
Data sources
We used data from two studies:
a)    The CARRS Cohort study was a population-based sam-
ple of urban adults in Chennai, New Delhi and Karachi 
established to assess the prevalence and incidence of 
cardio-metabolic diseases and their risk factors. Its 
details have been published previously17, in brief, par-
ticipants were selected in each city using multi-stage 
cluster random sampling with the Kish method18 to 
select only one man and one woman aged 20+ from each 
randomly selected household. Here we used baseline 
data from the cross-sectional survey conducted between 
October 2010, and December 2011 with mortality follow 
up through June 2014.
b)    The ICMR study was a cross-sectional survey conducted 
to estimate CVD risk factor prevalence in the National 
Capital Region of India (Delhi and Ballabgarh) in 
2010–201219. Multi-stage cluster random sampling was 
used for the primary sampling unit (household) selection. 
Data were collected on sociodemographic characteristics, 
CVD risk factors, treatment status, and measurements 
of height, weight, hip and waist circumference, and blood 
pressure. Fasting blood glucose (FBG) and lipids meas-
urements were done using fasting venous blood. Here 
we have included data only from the urban area of Delhi.
Risk calculation
Below we described the different steps we conducted to recalibrate 
the Framingham score
Step 1: Prognostic index or linear predictor calculation 
(i.e. Xi): We first calculated each individual Framingham “score” 
for CVD events in the next 10 years. This is a weighted sum of 
the individual’s characteristics using the Framingham weights 
(see Table 1).
Step 2: Reference individual survival calculation (S0): We 
then obtained the 2012 yearly mortality rates from CVD 
causes for India from WHO (0.003489 for men and 0.002646 
for women). We assumed that the ratio of non-fatal to fatal 
events was 2:1 so the yearly rates of total fatal and non-fatal 
            Amendments from Version 1
As we have not excluded patients with previous CVD in the 
CARRS cohort. Therefore, following the suggestion from the 
reviewer, we have re-done the analysis (results remain very 
similar) and had made this clear in the methods. We have also 
updated all the tables and figures accordingly.
To illustrate the contribution of each risk factor we have added 
two supplementary Figure-S1 & S2  It can be seen that age and 
BMI actually contribute to increasing the average score of men 
more than for women, but SBP (both treated and untreated) 
contribute more to increase the score in women. Adding up all 
these contributions women end up with a higher mean score than 




Page 3 of 21
Wellcome Open Research 2019, 4:71 Last updated: 27 OCT 2020
events was estimated as 3*0.003489 = 0.010467 for men 
and 3*0.002646 = 0.007938 for women. We assumed a con-
stant ratio, and therefore the probabilities of not having events 
in 10-years were (1 – 0.010467)10 = 0.90013 for men and 
(1 – 0.007938)10 = 0.923396 for women.
Step 3: Reference individual score calculation (X0): We then 
calculated three risks for each individual considering different 
values of scores and survivals: M1) using Framingham’s 
reference score and survival, M2) using a reference score (X
0
) 
derived from CARRS and estimated survival (S
0
) derived 
from WHO 2012 data for India (see above), and M3) using 
reference score (X
0
) derived from ICMR and the estimated 
survival (S
0
) derived from WHO 2012 data for India. We 
estimated the score of the “average individual” in the popula-
tion by multiplying the averages of the variables (in the log 
scale for the continuous variables) by the original Framingham 
coefficients and adding the values for all risk factors.
Step 4: Estimation of risks with different models: We calcu-
lated the risks for everyone in the CARRS and the ICMR datasets 
with three models (M1, M2, M3) using different combinations 
of reference score (X
0
) and survival probabilities (S
0
).
Comparison of risk and treatment
With each of the three risk calculations (M1. M2 and M3), we 
have stratified individuals in three different risk categories 
(<10%, 10–30%, and >30) which are commonly used for treat-
ment recommendations for antihypertensive and statins. To see 
how recalibration with one or another data set affects the propor-
tion of individuals treated, we have compared the proportion of 
individuals in the third risk category (>30%) between the 
different models. We reported the study following the TRIPOD 
statement20. A completed TRIPOD statement is available from 
OSF21. We used statistical package R, version 3.5.1 (2018-07-02)[1] 
for all our analysis
Results
Population characteristics
The CARRS study had data from 16,287 participants, but 
only 11,407 of those had the data needed to calculate the 
Framingham risk score (5,151 men and 6,256 women). The 
ICMR study had 3,075 individuals, but only 2,401 had all the data 
needed to calculate the score (1,089 men and 1,312 women).
In Table 2 we show the summaries statistics for each of the vari-
ables used in the Framingham score calculated in all the individuals 
that provided data for each variable separately.
In Table 3 below we report the reference scores using the 
Framingham, CARRS and ICMR populations, for this we have 
used the means of the log of the variables (which is not the 
same as the log of the mean). For example, for age, we first calcu-
lated a new variable “log(age)” for every single individual. Then 
we calculated the mean of this mean Mean[log(age)] =3.72033. 
Table 4 shows an example of the calculations using the 
CARRS population means.
Figure 1 shows the distribution of the recalibrated Framingham 
scores by sample and sex. Women have on average higher scores 
than men, and the Framingham ICMR recalibrated score has 
slightly higher means than the Framingham CARRS recalibrated 
in each sex.
Finally, in Table 5 we summarize the risk of the participants 
in both, CARRS and ICMR, estimated with the three different 
models for each sex/cohort. We present the mean risk and the 
distribution of the individuals in the three risk categories stated 
above (0–10%, 10–30%, and > 30%).
Table 2. Descriptive of risk factors in the two data sets *: mean (standard deviation).
MEN WOMEN
Data CARRS ICMR All CARRS ICMR All
Age* 42.9 (13.7) 47.2 (13.0) 43.6 (13.7) 41.1 (12.5) 45.2 (13.0) 41.8 (12.7)
BMI* 24.2 (4.6) 24.7 (6.1) 24.3 (4.9) 26.5 (5.5) 26.5 (5.5) 26.5 (5.5)
SBP* untreated 124.9 (17.7) 129.9 (19.4) 125.7 (18.0) 116.5 (17.9) 122.3 (19.6) 117.5 (18.4)
SBP* treated 139.7 (21.1) 143.9 (23.8) 140.7 (21.8) 136.5 (23.8) 143.6 (24.5) 138.1 (24.1)
Treatment 8.6% 13.8% 9.4% 13.6% 19.0% 14.5%
Smokers 27.1% 28.8% 27.3% 1.6% 3.3% 1.9%
Diabetics 26.0% 12.5% 23.5% 25.5% 10.7% 22.6%
BMI: body mass index, SBP: systolic blood pressure NOTE: We have removed patients with prevalent CVD from the 




Log of Age 3.11296 2.72107
Log of Body Mass Index 0.79277 0.51125
Log of SBP* if not treated 1.85508 2.81291
Log of SBP if treated 1.92672 2.88267
Smoking (0=No / 1=Yes) 0.70953 0.61868
Diabetes (0=No / 1=Yes) 0.53160 0.77763
* SBP: systolic blood pressure.
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Log of Age 3.11296*3.72033 2.72107*3.67602
Log of Body Mass Index 0.79277*3.17187 0.51125*3.25623
Log of SBP if untreated 1.85508*4.81871*0.8975 2.81291*4.74785*0.8553




Figure 1. Box-plots of the distribution of the Framingham scores by sex and study. CARRS: Centre for cArdiometabolic Risk Reduction 











WHO 2012 0.90013 0.92340
CARRS: Centre for cArdiometabolic Risk Reduction in 
South-Asia; ICMR: Indian Council of Medical Research; 
WHO: World health organization
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Table 5. Means of estimated risks and distribution by risk categories of individuals 
in each cohort with different estimation models: M-1) Framingham M-2) F-CARRS 
recalibrated and M-3) F- ICMR recalibrated. F: Framingham; CARRS: Centre for 
cArdiometabolic Risk Reduction in South-Asia; ICMR: Indian Council of Medical Research.
MEN WOMEN
Data/model Mean <=10% 10–30% >30% Mean <=10% 10–30% >30%
CARRS participants:
M1) Framingham 0.131 58.7% 29.2% 12.1% 0.060 82.0% 14.9% 3.1%
M2) F-CARRS 0.182 47.2% 32.2% 20.6% 0.149 60.2% 23.6% 16.1%
M3) F-ICMR 0.133 58.2% 29.4% 12.4% 0.114 67.6% 21.5% 11.0%
ICMR participants:
M1) Framingham 0.155 53.4% 30.7% 16.0% 0.079 76.5% 17.9% 5.6%
M2) F-CARRS 0.213 41.6% 32.6% 25.8% 0.188 51.7% 27.4% 20.9%
M3) F-ICMR 0.157 53.0% 30.5% 16.5% 0.145 60.6% 24.1% 15.3%
Effect of the recalibrated prognostic model on treatment
According to the WHO guidelines individuals with a risk of 
fatal or non-fatal cardiovascular event > 30% should get treat-
ment with statins23. In Figure 2 below we plot the difference in 
the proportion of individuals (by sex and cohort) that should 
be eligible for treatment according to the different models. 
For example, as shown in the red bar to the top-left graph of 
Figure 2, if we used model M2 instead of M1, about 8% more 
men in CARRS will be eligible for treatment. This can be calcu-
lated from the difference of 21.0% – 13.3% in Table 5 (first two 
rows for men). The pattern is very similar in both datasets within 
each sex. In men model M2 increases the proportion of men 
that should be treated compared to both model M1 and model 
M3, and M1 and M3 categorize men very similarly. For women, 
models M2 and M3 also increase the proportion of women that 
should be treated in comparison to M1, but in addition model, 
M2 also categorize more women than M3 as eligible to be treated.
Discussion
In this study, we calculated the 10-year Framingham CVD 
score in two cohorts of Indian urban populations (CARRS and 
ICMR) by using coefficients from a simplified Framingham 
model. We then predicted the risk in each cohort using three 
different models: one with the original Framingham reference 
coefficients and two recalibrated with the average risk factors 
prevalence in each of the datasets and the CVD mortality 
estimations for India from WHO-2012 data.
The average 10-year CVD risk estimates calculated using the 
Framingham recalibrated equation with the CARRS data was 
substantially higher than the original Framingham equation 
for both men and women, but the recalibrated equation using 
the ICMR the averages were only distinctly higher for women 
but not for men. A previous study in rural India, also found 
that the Framingham score underestimates in comparison with 
the one recalibrated with national data16. Other studies in South 
Asian Indian populations have also shown higher CVD incidence 
in comparison to the predicted by Framingham risk score24–27.
The overall CVD risk score is used to inform clinical decisions 
to start treatment to lower blood pressure and statins. The thresh-
olds recommended vary according to the guideline and settings. 
For example, the WHO guidelines recommend that individuals 
with a 30% 10-year risk of a fatal or non-fatal cardiovascular 
event should start with statins. Our study exemplifies that by 
using the prognostic model recalibrated with the CARRS data, 
there will be a substantial increase in the proportion of men 
and women that would be eligible for treatment with statins in 
comparison to the original Framingham risk score. However, 
by using the prognostic model recalibrated with the ICMR 
data, there would only be a substantial increase in the proportion 
of women that would be eligible for treatment.
To the best of the authors’ knowledge, this is the first large com-
munity-based study to recalibrate Framingham risk score in 
an urban population in India. One of our strengths is that the 
data are representative of their respective cities and that we 
used two different cohort studies. The main limitation is that we 
cannot check if the re-classification of the recalibrated model 
is indeed an improvement in risk prediction comparison 
with the original Framingham score because of the lack of 
cardiovascular events in the existing cohorts. Also, for the rec-
alibration we used WHO mortality data which includes a pop-
ulation with and without previous CVD, which might have 
overestimated the risk, however, until large and robust cohorts 
,with detailed outcome assessment, become available this is the 
best available dataset that can be used to estimate the expected 
mortality in patients without CVD.
Early identification and initiation of intensive primary preven-
tion among individuals with high risk of CVDs are critically 
important in reducing the CVD burden in India. Although, 
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almost all the major recent international guidelines including the 
National Institute for Health and Care Excellence (NICE) 2014 
guidelines, World Health Organization (WHO) 2007 guidelines, 
European Society of Cardiology (ESC) 2016 guidelines and the 
2017 American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines and national guideline unani-
mously recommend assessment of cardiovascular risk18,28–31, their 
adoption in primary prevention is suboptimal31–33. Few of com-
mon barriers for its decreased use are; lack of national guidelines, 
too many choices for CVD risk score, the uncertainty of validity 
of these risk score model in local context, time-consuming and 
lack of adjustment for the treatment34,35. Recalibrated model based 
on local population can improve the validity of the risk score 
model and reduce the perceived barriers of physician related to 
the local validity and enhance the use of CVD prediction model in 
the clinical setting for primary prevention. However, our study 
shows that even recalibrated models using data from the same 
country could be indeed very different and therefore it is vital to 
recalibrate models applying relevant local data (reflecting as best 
as possible local prevalence and overall mortality data). With the 
increasing use of technology, a possible approach could be to 
develop risk calculators in which local prevalent data and local 
incidence data is easily uploaded, and a “tailored” recalibrated 
model is provided for each setting. However, in the long-term 
future studies should develop CVD prognostic models using 
high quality and well powered local cohorts (with outcome data) 
and evaluate their implementation and impact. 
Valid and reliable local prognostic models will also be key 
to evaluate different high risk prevention strategies.  
Ethics and consent
CARRS (Centre for cArdiometabolic Risk Reduction in 
South-Asia) study was approved by the Institutional Review 
Boards (IRBs) of the Public Health Foundation of India, New 
Delhi (approval number: IRB00006658), All India Institute of 
Medical Sciences, New Delhi, Madras Diabetes Research 
Foundation, Chennai, India, Aga Khan University, Karachi, 
Pakistan, and Emory University, Atlanta, USA. ICMR (Indian 
Council of Medical Research) study was approved by All India 
Institute of Medical Sciences, New Delhi, ethics approval 
number is IEC/OP-05/06/09/10.
Figure 2. Difference in the proportion of treated individuals (risk > 30%) between the estimation of the three methods (M2-M1, M3-M1, 
and M2-M3). Bars reach the difference in proportions and segments represent 95% confidence intervals for the difference. M-1) Framingham 
M-2) F-CARRS recalibrated and M-3) F- ICMR recalibrated. F: Framingham; CARRS: Centre for cArdiometabolic Risk Reduction in South-Asia; 
ICMR: Indian Council of Medical Research
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Overall 
This paper has a clear and valid rationale, and clearly describes the approach used to recalibrate 
the available risk score to the two Indian cohorts. The discussion is clear and I agree with the main 
conclusion that “it is essential to develop high quality and well powered local cohorts (with 
outcome data) to develop local prognostic models”. 
  
Main comments 
The authors note that there is “no validated prognostic model for an Indian urban population” and 
so focus on recalibrating a Framingham equation developed in a completely different population. 
In 2018, the VIEW/PREDICT group in New Zealand published sex-specific risk scores for the 
primary prevention of CVD (Pylypchuk et al. Lancet 2018)1. As the scores were derived from a 
multi-ethnic cohort, they included a categorical variable for ethnicity, allowing risk to vary for the 
five largest defined ethnic groups in the country, one of which was Indian (derived from 14,188 
Indian women and 20,232 Indian men). Although the meaning of urban and rural will differ by 
country, the PREDICT cohort will be predominantly urban. I would suggest that the PREDICT risk 
scores are a more appropriate starting point for assessing risk in an Indian population. 
  
The CARRS and ICMR cohorts are population studies derived from sampling individuals per 
household, thus each cohort will include a mixture of people with and without CVD. I could not see 
anywhere that people with CVD were excluded, so my following comments assume they have 
remained in the cohorts.
The Framingham equation being referred to in this study is for people without CVD, and 
from the risk factors included, seems to be the 2008 score by D’Agostino et al.2 (the 
equation is not referenced in the current manuscript). What proportion of each cohort 
already had CVD and what was the composition of the disease? E.g., proportions with stroke 
vs MI vs peripheral vascular disease vs… etc. Could a difference in that composition have led 
to the difference in risk estimates using recalibrated risk scores in the two cohorts? 
 
○
The reference survival (So) was based on WHO estimated country-level mortality rates. This ○
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would be all-cause mortality, yet I believe the fatal component of the outcome predicted in 
the 2008 Framingham score is “coronary death”. It is fair enough to then estimate the non-
fatal events from a ratio, but it will multiplicatively amplify the non-fatal CVD event rate if 
based on all-cause deaths. 
 
The country-level mortality from WHO will include people from rural and urban areas, and 
people with and without existing CVD. Either of these factors may reduce its relevance to 
the cohorts being studied, and/or the risk score being investigated. 
○
A wording suggestion - the “Framingham score calculation (ie. Xi)” introduced on page 3 is more 
standardly called the prognostic index or linear predictor. 
  
As the authors note, a key limitation of the available data is that the predicted risks cannot be 
compared to actual event rates in the cohorts, so there is no way of knowing which version of the 
score is accurate, and if recalibration is even needed. This further supports the need for 
development of high quality local cohorts with outcome data. 
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Author Response 25 Nov 2019
Priti Gupta, Centre for Chronic Disease Control, India 
We thank the opportunity to respond to the reviewer very positive and helpful comments, 




This paper has a clear and valid rationale, and clearly describes the approach used to 
recalibrate the available risk score to the two Indian cohorts. The discussion is clear and I 
agree with the main conclusion that “it is essential to develop high quality and well powered 
local cohorts (with outcome data) to develop local prognostic models”. 
  
Main comments 
The authors note that there is “no validated prognostic model for an Indian urban 
population” and so focus on recalibrating a Framingham equation developed in a 
completely different population. In 2018, the VIEW/PREDICT group in New Zealand 
published sex-specific risk scores for the primary prevention of CVD (Pylypchuk et al. Lancet 
2018)1. As the scores were derived from a multi-ethnic cohort, they included a categorical 
variable for ethnicity, allowing risk to vary for the five largest defined ethnic groups in the 
country, one of which was Indian (derived from 14,188 Indian women and 20,232 Indian 
men). Although the meaning of urban and rural will differ by country, the PREDICT cohort 
will be predominantly urban. I would suggest that the PREDICT risk scores are a more 
appropriate starting point for assessing risk in an Indian population. 
  
The CARRS and ICMR cohorts are population studies derived from sampling individuals per 
household, thus each cohort will include a mixture of people with and without CVD. I could 
not see anywhere that people with CVD were excluded, so my following comments assume 
they have remained in the cohorts.
The Framingham equation being referred to in this study is for people without CVD, 
and from the risk factors included, seems to be the 2008 score by D’Agostino et al.2 
(the equation is not referenced in the current manuscript). What proportion of each 
cohort already had CVD and what was the composition of the disease? E.g., 
proportions with stroke vs MI vs peripheral vascular disease vs… etc. Could a 
difference in that composition have led to the difference in risk estimates using 
recalibrated risk scores in the two cohorts?
○
The reference survival (So) was based on WHO estimated country-level mortality 
rates. This would be all-cause mortality, yet I believe the fatal component of the 
outcome predicted in the 2008 Framingham score is “coronary death”. It is fair 
enough to then estimate the non-fatal events from a ratio, but it will multiplicatively 
amplify the non-fatal CVD event rate if based on all-cause deaths.
○
The country-level mortality from WHO will include people from rural and urban areas, 
and people with and without existing CVD. Either of these factors may reduce its 
relevance to the cohorts being studied, and/or the risk score being investigated. 
○
We thank for the reviewer for these thoughtful comments. We can confirm that the 
original analyses excluded patients with previous CVD in the ICMR cohort, but we have 
not excluded them in the CARRS cohort. Therefore, following the suggestion from the 
 
Page 13 of 21
Wellcome Open Research 2019, 4:71 Last updated: 27 OCT 2020
reviewer we have re-done the analysis (results remain very similar) and had made this 
clear in the methods. We have also updated all tables and figures accordingly. We 
agree that WHO data will include data with and without existing CVD but this is the 
best dataset that it is available to estimate the CVD mortality in India. While large and 
robust cohorts are unavailable re-calibration of existing models using the existing 
local data is the best approach we can take. We have added this as a potential 
limitation in the discussion.  
 
A wording suggestion - the “Framingham score calculation (ie. Xi)” introduced on page 3 is 
more standardly called the prognostic index or linear predictor. 
  
We have updated the text following the reviewer’s suggestion on page 3  
Competing Interests: No competing interests were disclosed.
Reviewer Report 30 April 2019
https://doi.org/10.21956/wellcomeopenres.16516.r35349
© 2019 Khaw K. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Kay Tee Khaw   
Gonville and Caius College, University of Cambridge, Cambridge, UK 
General comments 
Estimating an individual’s absolute risk of cardiovascular disease within the next 5 or 10 years is 
the basis of the “individual high risk” strategy to prevention of cardiovascular disease; those 
individuals identified at highest risk are targeted for established preventive interventions such as 
medications to lower blood cholesterol or blood pressure levels to reduce cardiovascular disease 
risk. 
  
Various risk algorithms are used, most of them based on some variant of the original Framingham 
cardiovascular risk score, using classical cardiovascular risk factors blood cholesterol, blood 
pressure, smoking, body mass index and diabetes as well as age and sex. 
 
The accuracy of risk algorithms for predicting cardiovascular disease risk in an individual therefore 
depends on a number of factors: 
Firstly, we require coefficients of risk for the different risk factors, that is how much the level or 
presence of a risk factor may increase future cardiovascular disease risk. While most may use a 
standard coefficient for each risk factor such as blood pressure, or smoking there may be variants 
on this such as different coefficients for different age groups, or men and women. 
Secondly we require the incidence of cardiovascular disease over the next ten years; again, these 
will differ in men and women and in different age groups as well as different populations, and 
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indeed over time with secular trends. 
In addition, in terms of public health implications, the proportion or numbers in the population 
who might be classified as high risk will also depend on the prevalence of the relevant risk factors 
in the different groups. 
The risk algorithms generally used in clinical and public health, such as the Framingham 
cardiovascular disease risk score are largely derived from data based originally on the 
Framingham Study or more recently variants of algorithms from other prospective studies mostly 
based in Western countries. 
The authors of this study make the very strong argument that though the burden of 
cardiovascular disease in India is huge, and increasing, there is a dearth of data on the use of such 
risk algorithms as applied to the Indian population, and no validated prognostic model for an 
Indian urban population 
 
They make the laudable attempt to recalibrate the original Framingham model using data from 
two urban Indian studies. They estimated three risk score equations using three different models. 
The first model was based on the Framingham original model, the second and third were 
recalibrated models using risk factor prevalence from the CARRS and ICMR studies and estimated 
survival from WHO 2012 data for India. They applied the three risk scores to the CARRS and ICMR 
participants and estimated the proportions of those at high risk (>30% 10 year CVD risk). The 
estimates of the proportions with such risk varied greatly using the different models. 
 
Their main conclusion was that their study exemplifies the variation between recalibrated models 
using different data from the same country. They state that it is essential to develop high quality 
and well powered local cohorts with outcome data to develop local prognostic models. While I 
would agree with the overall conclusions of the authors and support strongly the need for locally 
relevant population studies, there are a number of points that should be clarified in the text. 
 
Issues to consider in the manuscript 
The authors in this exercise state that they have recalibrated the original Framingham model 
using data from two urban Indian studies. They estimated three risk score equations using the 
first model based on the Framingham original model, the second and third were recalibrated 
models using risk factor prevalence from two Indian studies, the CARRS and ICMR studies and 
estimated survival from WHO 2012 data for India. 
 
A general comment: the text mostly refers to CVD (cardiovascular disease) risk but sometimes 
refers to CHD (coronary heart disease) risk. These are not the same: CVD includes CHD but is a 
larger category encompassing other conditions such as stroke etc so absolute rates are higher, 
and the relationship to risk factors is somewhat different. On page 3, there is a statement that the 
Framingham risk equation is a... method to measure coronary heart disease (CHD) risk but then 
later under Step 1 the Framingham score it is stated that this is it was calculated for CVD risk. Then 
in Step 2 the authors state that they obtained 2012 yearly mortality rates for CHD from India. Were 
the estimates for CVD or CHD? This materially affects the estimates of proportion with any given 
10 year absolute risk. In particular, there is a large male:female excess for coronary heart disease 
but generally stroke rates are more similar between men and women. This needs to be clarified 
throughout the manuscript. 
 
Most approaches estimating the proportion of those with a given 10 year CVD (or CHD) risk in a 
defined population (e.g. >30% 10 years or >20% 10 years) generally apply the Framingham 
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coefficients to derive individual Framingham risk scores. The proportion with a high score thus 
relies both on the coefficients used and the prevalence of risk factors in the population which may 
vary in different populations. This can be done with cross sectional data in which data on risk 
factors are available using the Framingham risk score. This was done in Step 1 by the authors 
using cross sectional data from the two Indian studies: CARRS and ICMR. 
 
The authors then proceeded to develop a model based on 2012 yearly mortality rates for CHD (as 
stated in the text rather than CVD) for India from WHO (page 3, Step 2). From what I understand, 
they then derived the average probability of not having events in 10 years for men and women 
separately. It would seem that because a longitudinal population cohort with individual follow up 
and endpoints was not available, the WHO data were used to approximate the data to estimate 
the score of the “average individual in the population by multiplying the averages of the variables 
by the original Framingham coefficients and adding the values for all risk factors”. 
 
Then in Step 4 they calculated the risks for everyone in the CARRS and ICMR data sets with the 3 
models using different combinations of reference score and survival probabilities. 
I found Steps 2-4 rather hard to follow and it would particularly have been helpful to know more 
about the assumptions they used in applying the WHO 2012 mortality dataset (apart from the 
CHD/CVD distinction). For example, they state they used the total CHD annual mortality- was this 
age standardised, or if not, was this for the whole population or a subset of the population? 
Presumably the CARRS and ICMR studies encompassed the whole adult age range but it would be 
helpful to have some more information about the age distribution the rates of cardiovascular 
disease are so strongly age related. The estimates of the proportion of the population at high 
cardiovascular risk over 10 years must surely depend hugely on the age distribution of the 
population, and the Framingham algorithms were derived on a slightly older age distribution than 
20year + (CARRS). 
 
Table 1 shows coefficients from the simplified Framingham model. There are a number of 
references to the Framingham model cited which I have looked up, and I may have missed this, 
but it would be helpful to cite the exact reference for coefficients used in this table. I was rather 
surprised for example, in the sex specific coefficients that the women had different coefficients 
from men for many of the risk factors, whereas in many of the Framingham algorithms that I have 
seen, the sexes are combined for risk factors with a weighting for male vs female. Body mass 
index, age, and smoking appear to be more weighted in men whereas blood pressure, and 
diabetes are more highly weighted in women. This is relevant when considering results. 
 
The tables are clearly presented showing the risk factor distribution in the two population datasets 
from India (Table 2) and reference scores and survivals in Table 3. The examples of reference 
score calculations using means from the CARRS population in Table 4 is also of interest with 
similar differential weighting of the risk factors in men and women as with the Framingham study. 
However, the results that were surprising were that women in Tables 4 and Figure 1 appeared to 
have higher Framingham scores. In Table 5, however, it seems that while there was a much higher 
proportion of men with >30% risk compared to women using the Framingham risk score, the 
proportions of men and women were much more similar using the F-CARRS or F-ICMR derived 
scores. Given that the prevalence of risk factors in women in both CARRS and ICMR were generally 
lower in women than men apart from body mass index (Table 1), and that women had lower 
mortality (CHD or CVD) than men this does not really make sense. I wonder whether this may be a 
consequence of the modelling, (CHD/CVD mortality) or insufficient account of the age distribution. 
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Perhaps they could check their models. 
 
Minor points 
The introduction makes a strong argument about the importance of cardiovascular disease in 
India. However, some of the statements may need some nuance. The statement that the all age 
death rate increased significantly between 1990 and 2016 for ischemic heart disease. This may 
reflect both increasing age specific mortality from heart disease or major demographic shifts that 
is ageing of the population as ischemic heart disease rates increase with age and the numbers 
and proportion of older people in India have increased over that time period. (In the USA, absolute 
CVD deaths have increased over the last few decades despite declining age specific or age 
standardised rates, simply because of the increased numbers of older people). Similarly though, 
the statement that Indians are affected by CVDs at a younger age compared to their European 
counterparts may well be true, the statement that more than 50% CVD deaths occur before the 
age of 70 years may reflect the much younger age distribution of the population – comparisons of 
risk are not robust without appropriate denominators. 
 
Though the methods used and estimates of proportions at different levels of absolute risk can be 
discussed, the authors have made the point clearly. I think this manuscript indeed does illustrate 
and highlight the extraordinary discrepancy between the large and increasing burden of 
cardiovascular disease in emerging economies globally and the paucity of locally relevant data; 
they have provided an example of where such local data can be used and the great need for 
relevant evidence and support of ongoing population studies to inform policy and practice. 
As an aside, though not the focus of this manuscript, whatever the model used, the estimates 
indicate the very high proportion of the population with high absolute cardiovascular risk and 
challenges of the individual high risk strategy in countries such as India. The discussion is careful 
and considered in terms of the various guidelines for identifying high risk individuals for 
preventive interventions but perhaps might also point out the value of local population studies for 
providing the evidence base for mass preventive strategies.
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 25 Nov 2019
Priti Gupta, Centre for Chronic Disease Control, India 
We thank the opportunity to respond to the reviewers’ very positive and helpful comments, 




A general comment: the text mostly refers to CVD (cardiovascular disease) risk but 
sometimes refers to CHD (coronary heart disease) risk. These are not the same: CVD 
includes CHD but is a larger category encompassing other conditions such as stroke 
etc so absolute rates are higher, and the relationship to risk factors is somewhat 
different. On page 3, there is a statement that the Framingham risk equation is a... 
method to measure coronary heart disease (CHD) risk but then later under Step 1 the 
Framingham score it is stated that this is it was calculated for CVD risk. Then in Step 2, 
the authors state that they obtained 2012 yearly mortality rates for CHD from India. 
Were the estimates for CVD or CHD? This materially affects the estimates of 
proportion with any given 10-year absolute risk. In particular, there is a large male: 
female excess for coronary heart disease but generally stroke rates are more similar 
between men and women. This needs to be clarified throughout the manuscript.
○
Response: We thank the reviewer for identifying this inconsistency. The Framingham 
score we used estimates the probability of CVD and that is what we meant and 
accordingly we have obtained the corresponding India CVD 2012 mortality rate. We 
have now edited the manuscript accordingly.
Most approaches estimating the proportion of those with a given 10 year CVD (or 
CHD) risk in a defined population (e.g. >30% 10 years or >20% 10 years) generally 
apply the Framingham coefficients to derive individual Framingham risk scores. The 
proportion with a high score thus relies both on the coefficients used and the 
prevalence of risk factors in the population which may vary in different populations. 
This can be done with cross sectional data in which data on risk factors are available 
using the Framingham risk score. This was done in Step 1 by the authors using cross 
sectional data from the two Indian studies: CARRS and ICMR. 
The authors then proceeded to develop a model based on 2012 yearly mortality rates 
for CHD (as stated in the text rather than CVD) for India from WHO (page 3, Step 2). 
From what I understand, they then derived the average probability of not having 
events in 10 years for men and women separately. It would seem that because a 
longitudinal population cohort with individual follow up and endpoints was not 
available, the WHO data were used to approximate the data to estimate the score of 
the “average individual in the population by multiplying the averages of the variables 
○
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by the original Framingham coefficients and adding the values for all risk factors”. 
Then in Step 4 they calculated the risks for everyone in the CARRS and ICMR data sets 
with the 3 models using different combinations of reference score and survival 
probabilities. I found Steps 2-4 rather hard to follow and it would particularly have 
been helpful to know more about the assumptions they used in applying the WHO 
2012 mortality dataset (apart from the CHD/CVD distinction). For example, they state 
they used the total CHD annual mortality- was this age standardised, or if not, was 
this for the whole population or a subset of the population? Presumably the CARRS 
and ICMR studies encompassed the whole adult age range but it would be helpful to 
have some more information about the age distribution the rates of cardiovascular 
disease are so strongly age related. The estimates of the proportion of the population 
at high cardiovascular risk over 10 years must surely depend hugely on the age 
distribution of the population, and the Framingham algorithms were derived on a 
slightly older age distribution than 20year + (CARRS).
  
Response: We thank the reviewer for the comments, and we hope the answer below 
clarified the procedure we followed
We did not develop a “de novo” risk score model (i.e. we cannot calculate 
coefficients for the different risk factors because, as the reviewer points out, we 
have no follow up and outcomes), we use instead the coefficients from the 
existing Framingham model. What we did is to re-calibrate this model to the 
Indian data that we are going to predict.
1. 
To re-calibrate a model in a new dataset we need a “reference individual”, i.e. an 
individual with a known value of Framingham score and known risk of having a 
cardiovascular event.The risk of any other individual is calculated depending on 
the difference between that individual’s score and the reference individual’s 
score.The question is then, how to find the reference individual. In reality no 
one has a reference individual in our data, so we have to make assumptions. 
One option is to assume that the population CV risk estimated by the WHO 
studies would be the risk of a person with average score in the Framingham 
model in our Indian sample. And so the reference individual will be a person 
with score produced by setting all variables to the average value and we will 
assume that their risk is precisely the population CVD risk estimated by WHO.
2. 
WHO estimates of death rates were calculated standardizing by age with the 
WHO standard population for individuals between 30 and 70 years old.
3. 
Table 1 shows coefficients from the simplified Framingham model. There are a 
number of references to the Framingham model cited which I have looked up, and I 
may have missed this, but it would be helpful to cite the exact reference for 
coefficients used in this table. I was rather surprised for example, in the sex specific 
coefficients that the women had different coefficients from men for many of the risk 
factors, whereas in many of the Framingham algorithms that I have seen, the sexes 
are combined for risk factors with a weighting for male vs female. Body mass index, 
age, and smoking appear to be more weighted in men whereas blood pressure, and 
diabetes are more highly weighted in women. This is relevant when considering 
results.
○
Response: We have indeed used the Framingham sex specific coefficients available on 
supplementary table 1 of D’Agostino et al. General Cardiovascular Risk Profile for Use 
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in Primary Care The Framingham Heart Study. Circulation. 2008;117: 743-753. We have 
now made it clearer and included this reference in the methods and tables i.e new 
reference number 3.
The tables are clearly presented showing the risk factor distribution in the two 
population datasets from India (Table 2) and reference scores and survivals in Table 
3. The examples of reference score calculations using means from the CARRS 
population in Table 4 is also of interest with similar differential weighting of the risk 
factors in men and women as with the Framingham study. However, the results that 
were surprising were that women in Tables 4 and Figure 1 appeared to have higher 
Framingham scores. In Table 5, however, it seems that while there was a much 
higher proportion of men with >30% risk compared to women using the Framingham 
risk score, the proportions of men and women were much more similar using the F-
CARRS or F-ICMR derived scores. Given that the prevalence of risk factors in women in 
both CARRS and ICMR were generally lower in women than men apart from body 
mass index (Table 1), and that women had lower mortality (CHD or CVD) than men 
this does not really make sense. I wonder whether this may be a consequence of the 
modelling, (CHD/CVD mortality) or insufficient account of the age distribution. 
Perhaps they could check their models.
○
Response: We thank the reviewer for this comment, and we understand the results 
appear to be counter-intuitive if one considers that women seem to have lower levels 
of risk factor than men in this population. However, it is important to consider the 
coefficients multiplying the risk factors when we calculate the score. For example, the 
coefficients for SBP, both treated and untreated, are higher in women than men, and 
this is a key factor that adds much weight to the score. Even if women have lower SBP 
mean than men, when multiplied by the coefficient this increases more their score 
than in men. To illustrate the contribution of each risk factor we have added a figure 
in the appendix (see Figure-S1).  It can be seen that age and BMI actually contribute to 
increase the average score of men more than for women, but SBP (both treated and 
untreated) contribute more to increase the score in women. Adding up all these 
contributions women end up with a higher mean score than men in both data sets. 
  
Finally, the conversion of the score to a risk factor depends on the re-calibration (the 
choice of “reference individual” as explained in our response to your question 2).   If 
the score of the reference individual is lowered but while their risk is kept the same, 
the predicted risks of all other individuals in the data will increase.  To illustrate this, 
we have created another plot (see Figure-S2) where we show how the same 
distribution of risk scores is converted into different distribution of predicted risks 
depending on the recalibration model. 
  
Minor points
The introduction makes a strong argument about the importance of cardiovascular 
disease in India. However, some of the statements may need some nuance. The 
statement that the all age death rate increased significantly between 1990 and 2016 
for ischemic heart disease. This may reflect both increasing age specific mortality 
from heart disease or major demographic shifts that is ageing of the population as 
ischemic heart disease rates increase with age and the numbers and proportion of 
older people in India have increased over that time period. (In the USA, absolute CVD 
○
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deaths have increased over the last few decades despite declining age specific or age 
standardised rates, simply because of the increased numbers of older people). 
Similarly though, the statement that Indians are affected by CVDs at a younger age 
compared to their European counterparts may well be true, the statement that more 
than 50% CVD deaths occur before the age of 70 years may reflect the much younger 
age distribution of the population – comparisons of risk are not robust without 
appropriate denominators.
Response: We agree with the reviewer that there are two issues regarding the 
statement that CVD affect Indian as a younger age. We have now made it clear that it 
related both to a demographic age distribution of age plus an increased in age 
standardized age for CVD.  
We have added following line with reference: 
“Age adjusted prevalence of CVDs have also increased in India(1,2)”
Though the methods used and estimates of proportions at different levels of absolute 
risk can be discussed, the authors have made the point clearly. I think this manuscript 
indeed does illustrate and highlight the extraordinary discrepancy between the large 
and increasing burden of cardiovascular disease in emerging economies globally and 
the paucity of locally relevant data; they have provided an example of where such 
local data can be used and the great need for relevant evidence and support of 
ongoing population studies to inform policy and practice. As an aside, though not the 
focus of this manuscript, whatever the model used, the estimates indicate the very 
high proportion of the population with high absolute cardiovascular risk and 
challenges of the individual high risk strategy in countries such as India. The 
discussion is careful and considered in terms of the various guidelines for identifying 
high risk individuals for preventive interventions but perhaps might also point out the 
value of local population studies for providing the evidence base for mass preventive 
strategies.
○
Response: We thank the reviewer for the positive comments about our discussion and 
we agree about the implications of local studies for providing evidence for preventive 
strategies. We have now edited the discussion section accordingly and inlcuded 
following lines: 
“Also, for the recalibration we used WHO mortality data which includes a population 
with and without previous CVD, which might have overestimated the risk, however, 
until large and robust cohorts ,with detailed outcome assessment, become available 
this is the best available dataset that can be used to estimate the expected mortality 
in patients without CVD.” 
“Valid and reliable local prognostic models will also be key to evaluate different high 
risk prevention strategies.”  
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